Evelo Biosciences reported a net loss of $21.1 million for the second quarter of 2023, with cash and cash equivalents at $7.6 million as of June 30, 2023. The company is on track for a top line read-out from their Phase 2 study in moderate psoriasis with EDP2939 early in the fourth quarter of 2023 and completed a $25.5 million private placement.

Evelo Biosciences reported a net loss of $23.5 million for the fourth quarter of 2022, with cash and cash equivalents totaling $47.9 million as of December 31, 2022. The company progressed its SINTAX platform and clinical pipeline, with upcoming clinical milestones expected in 2023.

Evelo Biosciences reported a net loss of $30.6 million for the third quarter of 2022, with cash and cash equivalents totaling $69.1 million as of September 30, 2022. The company is progressing with its clinical programs, including EDP1815 in atopic dermatitis and psoriasis, and EDP2939 in psoriasis, with multiple Phase 2 data readouts expected in 2023.

Evelo Biosciences reported a net loss of $30.6 million for Q2 2022, with cash and cash equivalents at $92.0 million. The company is progressing with clinical trials for EDP1815 and EDP2939, expecting key data readouts in the coming quarters.

Evelo Biosciences reported first quarter 2022 financial results, highlighting positive data for EDP1815 in psoriasis and the advancement of EDP1815 towards later-stage clinical trials. The company's cash and cash equivalents were $39.6 million as of March 31, 2022.

Evelo Biosciences reported a net loss of $28.7 million for the fourth quarter of 2021, with R&D expenses at $18.9 million and G&A expenses at $8.7 million. Cash and cash equivalents were $68.4 million as of December 31, 2021.

Evelo Biosciences reported a net loss of $31.6 million for the second quarter of 2021, with cash and cash equivalents totaling $123.3 million as of June 30, 2021. The company is advancing its clinical development programs, including EDP1815 in psoriasis and atopic dermatitis, and expects multiple clinical data readouts over the next 6-12 months.

Evelo Biosciences reported its Q1 2021 financial results, highlighting positive data from the Phase 1b clinical trial of EDP1815 for atopic dermatitis and a strategic collaboration with Abdul Latif Jameel Health. The company also strengthened its leadership team with new appointments.

Evelo Biosciences announced positive clinical data readout with EDP1815 and reported financial results for the fourth quarter and full year 2020. The company initiated a Phase 1b clinical trial of EDP1867 in atopic dermatitis and strengthened its balance sheet with $88 million in net proceeds from recent sales of common stock.

Evelo Biosciences reported its third quarter 2020 financial results, highlighting progress in clinical trials for EDP1815 in psoriasis and atopic dermatitis, as well as advancements in their SINTAX-based medicine platform. The company anticipates six clinical readouts over the next 3-9 months and is progressing with preclinical development of microbial extracellular vesicles.

Evelo Biosciences reported its second quarter 2020 financial results, highlighting the advancement of its programs in psoriasis, COVID-19, atopic dermatitis, and triple-negative breast cancer (TNBC).

Evelo Biosciences reported its Q1 2020 financial results, highlighting clinical advancements with EDP1815 and EDP1503, including an IND submission for a Phase 2 trial of EDP1815 for COVID-19 and a focus on the triple-negative breast cancer cohort for EDP1503. The company's cash and cash equivalents decreased to $58.1 million, and the net loss was $23.0 million, or $(0.71) per share.

Evelo Biosciences reported positive clinical data supporting the validation of its novel platform and demonstrating the targeting of SINTAX™ to drive clinical effects in individuals with psoriasis. Multiple clinical readouts are planned across the inflammation and oncology portfolio in 2020, and the development of EDP1815 is progressing.